Skip to main content
Orphanet Journal of Rare Diseases logoLink to Orphanet Journal of Rare Diseases
letter
. 2023 Oct 19;18:330. doi: 10.1186/s13023-023-02904-1

Does the registry speak your language? A case study of the Global Angelman Syndrome Registry

Megan Tones 1,, Nikolajs Zeps 1, Yvette Wyborn 1, Adam Smith 1, Roberto A Barrero 1, Helen Heussler 2, Meagan Cross 3, James McGree 4, Matthew Bellgard 1,5,
PMCID: PMC10588126  PMID: 37858180

Abstract

Global disease registries are critical to capturing common patient related information on rare illnesses, allowing patients and their families to provide information about their condition in a safe, accessible, and engaging manner that enables researchers to undertake critical research aimed at improving outcomes. Typically, English is the default language of choice for these global digital health platforms. Unfortunately, language barriers can significantly inhibit participation from non-English speaking participants. In addition, there is potential for compromises in data quality and completeness. In contrast, multinational commercial entities provide access to their websites in the local language of the country they are operating in, and often provide multiple options reflecting ethnic diversity. This paper presents a case study of how the Global Angelman Syndrome Registry (GASR) has used a novel approach to enable multiple language translations for its website. Using a “semi-automated language translation” approach, the GASR, which was originally launched in English in September 2016, is now available in several other languages. In 2020, the GASR adopted a novel approach using crowd-sourcing and machine translation tools leading to the availability of the GASR in Spanish, Traditional Chinese, Italian, and Hindi. As a result, enrolments increased by 124% percent for Spain, 67% percent for Latin America, 46% percent for Asia, 24% for Italy, and 43% for India. We describe our approach here, which we believe presents an opportunity for cost-effective and timely translations responsive to changes to the registry and helps build and maintain engagement with global disease communities.

Keywords: Disease Registry, Patient reported outcomes, Language translation, Equity diversity and inclusion

Background

Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by dysfunction of the maternally inherited UBE3A gene. It is estimated that 500,000 people live with AS worldwide [1]. Global rare disease registries are a valuable tool for enhancing therapeutics in rare diseases, enabling participant recruitment and capture and monitoring of patient reported outcomes, amongst other uses. Despite the need to be Global, there is a lack of diversity in terms of language available on global registry websites. This is, unfortunately, common in medicine and science where the fact that the common scientific language is English has spilled over into an apparent insistence that participants in research from non-English speaking countries must be done in English. In contrast, no multinational commercial entity would survive if it took this approach and as a result, they are available in myriad local languages. For Example, the website for the global movement Rare Disease Day is available in 103 languages besides English [2], while the European Commission websites strive to be available in all 24 recognised European languages [3]. Registry development guidelines including the fourth edition of the guide Registries for Evaluating Patient Outcomes released by the Agency for Healthcare Research and Quality [4] and Rare Diseases Registry Program [5], stress the importance of careful translation of multinational registries. Other international registries such as the Hyperinsulinism Global Registry or Global Prader Willi Registry are intending to incorporate multiple languages [6, 7]. Another strategy is to establish a federation of linked registries for a rare disease to achieve global coverage of patients [8]. Towards this end, the Global Angelman Syndrome Registry is open to data linkages with other data sets including Natural History Studies and registries such as the Angelman Syndrome Online Registry [9]. Barriers to making services multilingual include lack of access to translators, and the need for technical expertise or an understanding of the topic of the registry. Tools such as google translate have demonstrated that technology can be used to assist with this, although native speaker input is still required to ensure accuracy and readability of translations.

Findings from a review of articles on methodological approaches to the cross-cultural adaptation of surveys and tools indicated that translators should be fluent in the source and target languages, understand both cultures, and knowledgeable about the content of the instrument being adapted [10]. Addressing each of these requirements may be challenging, as professional translators may not be subject matter experts and will lack specialised content knowledge. Involving more than one translator in the process may be beneficial to offer a mix of perspectives with respect to language fluency, cultural understanding, and content knowledge. However, this may prove difficult due to challenges around document sharing version control, and managing division of workload inhibiting translator interactions. Additionally, reconciliation and review of translations by an expert panel, and cognitive interviews or pilot testing with focus groups should be undertaken to determine the face and content validity of translated instruments [10]. There is limited evidence the value of back translations [10].

Use of technology to facilitate translations

Machine translation (MT) involves using software tools to translate text or speech from the source language to the target language [11]. The process is automated and may involve different approaches including rules created by linguists and computer scientists, examples from a database of source and target language sentences, and statistical modelling of the probability that a target sentence is the correct translation of a source sentence [12].

Translation memories (TM) are a related technology which involves storing previously completed human translations, including the source text and translated text, in a database and matching segments of text, such as a sentence, from the TM database with new source text to create translations [13]. Matches may be exact, or identical including formatting; full, with differences such as numbers or dates; or fuzzy, which is similar but requires editing [13].

Crowdsourcing refers to an organisation (such as a research institution or not for profit) outsourcing a task previously undertaken internally to an external community to complete a task or solve a problem for mutual benefit [14]. In research, crowdsourcing has been used for a range of tasks including identification and classification, transcription or translation, and data collection and analysis [15]. Organisations including Cochrane and Technology, Entertainment and Design (TED) talks involve volunteer translators to translate resources in recognition of the fact that most people globally do not speak English as a first language [16].

Rare disease registries may present a unique opportunity for crowdsourcing translations, as rare disease communities often drive the development of registries and have strong involvement in registry governance and ownership. While crowdsourcing may seem advantageous in this context, projects must be managed effectively to prevent negative outcomes such as translator or researcher burnout or malicious translations. Blohm et al. [17] reviewed the management and governance of a variety of crowdsourcing projects and determined a four-step process for running a crowdsourcing project: (1) Define Goal and System Type; (2) Start Small and Experiment; (3) Build up Scalable Structures and (4) Adapt and Monitor Governance (p. 143).

Current study

The Global Angelman Syndrome Registry was launched in English in September 2016 [18]. The registry was sponsored by the Foundation for Angelman Syndrome Therapeutics (FAST) Australia. The aims of the registry include:

  1. Facilitate participant recruitment for clinical trials;

  2. Collect the natural history of a large cohort of individuals with AS;

  3. Identify demographic, phenotypic and genotypic variation in clinical features and outcomes; and

  4. Aid in service provision planning for individuals with AS and their families.

The registry was originally deployed using the Rare Disease Registry Framework (RDRF) [1833], an internet-based modular registry framework, developed by the Centre for Comparative Genomics at Murdoch University.

Since its launch, AS organisations have expressed an interest in translation into multiple languages. Initially, the translation process was to include three steps: (1) Forward translation; (2) Back translation; and (3) Pilot testing. The forward translation process was completed for Italian, Spanish, French and Hebrew, and partially completed for Portuguese and Chinese.

In 2020, the registry was moved to the Trial Ready Registry Framework (TRRF) [30, 32, 3439]. The new platform incorporated significant revisions based on feedback from families, clinicians and researchers. Changes included revisions to both content and functionality to simplify the user experience in completing forms, enable longitudinal data collection and user managed linkages with clinicians and researchers, and integrate translations and analytics.

Due to changes to the registry content and function, and the likelihood of the requirement for updates for existing translations and the addition of more languages, alternative methodologies for translations were explored that were less burdensome on the community and research team. The current study reports on the establishment of the GASR translation project.

Method

To facilitate timely translation of the GASR, Crowdin [40] was selected as a tool to integrate existing translations (converted to TM) and MT provided by Crowdin software with crowdsourcing translations from the Angelman community and manage the translation process.

Registry description

The GASR features a series of forms, or modules that collect information on an individual with AS’s condition. The forms cover demographic, clinical, behavioural and developmental information. The content of the GASR modules and other patient facing information including the registration form, standard emails, and website messages constituted the information to be translated. There were approximately 13 000 words on the GASR across the 20 sections to be translated.

Prior to the availability of the translations, 1625 families have joined the registry, 1614 of whom had provided geographic data. As shown in Table 1, most families were from English speaking countries.

Table 1.

Country/region of residence, families in the Angelman Registry Prior to Translation Availability

Country N %
United States 712 44.3
Australia 166 10.3
Canada 95 5.9
United Kingdom 89 5.5
Brazil 65 4.0
Germany 42 2.6
Poland 42 2.6
Italy 41 2.5
Spain 37 2.3
Chile 29 1.8
Western Asia 23 1.4
Colombia 22 1.4
Greece 21 1.3
India 21 1.3
France 18 1.1
New Zealand and the Pacific 16 1.0
Russia 16 1.0
Argentina 14 0.9
Latin America and the Carribbean 14 0.9
Northern Europe 13 0.8
Western Europe 13 0.8
Netherlands 12 0.7
Southern Europe 11 0.7
Eastern Europe 11 0.7
Eastern Asia 10 0.6
Ireland 10 0.6
Mexico 9 0.6
Northern Africa 8 0.5
Hungary 6 0.4
Portugal 6 0.4
South Africa 6 0.4
South-eastern Asia 5 0.3
Southern Asia 5 0.3
Total 1608 100

Governance and management of crowdsourcing

A Crowdin Enterprises project, hereafter referred to as Crowdin, (https://eresearchqut.crowdin.com/) was established to manage the project. Crowdin allows for different levels of access to ensure that participants only have access to tasks to which they are assigned by the project administrator. As the registry was pre-translated, the volunteers were assigned one of two roles: community proofreader or final proofreader. Community proofreaders review and modify existing machine translations, while final proofreaders are trusted professionals from the AS community who review and correct community proofread translations.

Proofreaders access the registry content via a testing site located at https://trrf.qa.angelmanregistry.info/. The website enables users to view the translations in the context of the website and access the Crowdin editor tool for each string. The editor tool shows the source text and several translations obtained from translation memory files or machine translations. The proofreader can revise, add or approve translations, and leave comments for other project team members.

Community proofreaders participated in a small group training session with one of the authors (M.T.), who explained the workflow of the project and how to use the Crowdin tool. For the purposes of scalability, one language was selected for pilot testing and refining the translation process. To date, training sessions have been held with community proofreaders for the Italian, Spanish, Chinese, Portuguese and French languages. Hindi was subsequently translated by an external company capable of interfacing with Crowdin.

The author running the training sessions checked in with a nominated translator from each group weekly to receive updates about progress and obtain feedback.

Research ethics

The registry team submitted ethics amendments to incorporate translations into the protocol. Approval was granted for the translation of registry materials using the methods described above from the Mater Health Services Human Research Ethics Committee (HREC/13MHS/76/ Project 20,865).

Results

The Spanish, Traditional Chinese, Italian and Hindi versions of the registry were launched in 2022 on the 6th January, 22nd March, 27th of April and 13th October respectively. Growth in registry enrolments post translations for each country or region where the language is spoken are shown in Fig. 1, along with current totals.

Fig. 1.

Fig. 1

Growth in registry participation pre and post translations

Observations and feedback from the translation process

The Crowdin tool was user friendly. Proofreaders utilised a mix of the Crowdin editor tool and in-context editing tool. The editor tool displayed the source text and available translations side by side, enabling users to correct existing translations or add new translations. The Crowdin editor tool was the primary method used for proofreading, as all strings were displayed in the interfacing, ensuring comprehensive proofreading. The in-context editing tool was implemented on a test website which replicated the GASR site, which was valuable to view how the translations would appear to users in the context of the registry. A list of examples of source text, machine translations, and community and professional proofreading corrections is shown in Table 2.

Table 2.

Example of source text with machine translations, and community and professional proofreading corrections

Source text Machine translations Community translations Professional translations
Italian
On a typical day, how many hours do they spend using the device for AAC purposes? In una giornata tipica, quante ore trascorrono a utilizzare il dispositivo per scopi AAC? In una giornata tipica, quante ore spendono usando il dispositivo per scopi CAA? In una giornata tipica, per quante ore il bambino/adulto utilizza il dispositivo per la CAA?
Gross Motor Function—please describe your child/adult's ability to do the following: Funzione motoria lorda: descrivi la capacità di tuo figlio/adulto di fare quanto segue: Funzione grosso motoria—descrivere la capacità del paziente di fare quanto segue: Abilità grosso motorie—descrivere la capacità del paziente di fare quanto segue:
Please report on your child/ adult's current seizure status Si prega di riferire sullo stato attuale delle crisi epilettiche di suo figlio/adulto Si prega di segnalare lo stato attuale del quadro epilettico del paziente Si prega di segnalare lo stato attuale del quadro epilettico del paziente
Please tell us what medications/interventions your child/ adult is currently taking Dicci quali farmaci/interventi sta attualmente assumendo tuo figlio/adulto Per favore, indica quali farmaci o quali terapie sono attualmente somministrati al paziente Per favore, indica quali farmaci o quali trattamenti sono attualmente somministrati al paziente
Spanish
Adaptive Behaviour: Dressing—please describe your child/adult's ability to do the following: Comportamiento adaptativo: cómo vestirse: describa la capacidad de su hijo/adulto para hacer lo siguiente: Comportamiento Adaptativo: Vestirse- por favor describe la capacidad de su niño/adulto para hacer lo siguiente: Comportamiento Adaptativo: Vestirse- por favor describa la capacidad de su niño/adulto para hacer lo siguiente:
For what function of communication does your child/ adult use AAC with you? ¿Para qué función de comunicación usa su hijo/adulto el AAC con usted? ¿Para qué función de comunicación su hijo/adulto utiliza CAA con usted? ¿Para qué función de comunicación su niño/adulto utiliza CAA con usted?
Individual with Angelman Syndrome's Results Resultados de una persona con síndrome de Angelman Resultados del Individuo con Síndrome de Angelman Individuo con los resultados del Síndrome de Angelman
What was your child/ adult's age when medication/ intervention was started? ¿Cuál era la edad de su hijo o adulto cuando comenzó la medicación o la intervención? ¿Cuál era la edad de su niño/adulto cuando se inició la medicamento/intervención? ¿Cuál era la edad de su niño/adulto cuando se inició la medicación /intervención?
Traditional Chinese
Would you describe your child/ adult’s gait as typical when compared to typically developing age matched peers? 與通常發展中的年齡匹配的同齡人相比, 您會將您的孩子/成人的步態描述為典型嗎? 與一般發展年齡相符的同齡人相比, 您會將您的孩子/患者的步態形容為典型嗎? 與相同發展年齡的一般人相比, 您會形容您的孩子/患者步態正常嗎?
How is the constipation (or regular bowel function) managed? 如何管理便秘 (或正常排便功能) ? 便秘(或定期腸功能)是如何管理的? 便秘(或定期排便功能) 是如何管理的?
How would you describe your child/ adults’ muscle tone? 你會如何形容你的孩子/成人的肌肉張力? 你會如何形容你的孩子/患者的肌肉活動? 你會如何形容你的孩子/患者的肌肉張力?
Has your child/ adult had any other medical conditions that have not been covered? 您的孩子/成人有沒有受保的其他醫療狀況? 您的孩子/患者有否其他未包括的醫療狀況? 您的孩子/患者有否其他未包括的疾病?
Hindi
Is your child/ adult currently participating in Augmentative and Alternative Communication (AAC) therapy? क्या आपका बच्चा/वयस्क वर्तमान में ऑगमेंटेटिव एंड अल्टरनेटिव कम्युनिकेशन (AAC) थेरेपी में भाग ले रहा है? क्या आपका बच्चा/वयस्क वर्तमान में ऑगमेंटेटिव एंड अल्टरनेटिव कम्युनिकेशन (AAC) थेरेपी में भाग ले रहा है?
Were there any reflux/gastro/oesophageal problems? क्या कोई रिफ्लक्स/गैस्ट्रो/ओसोफेगल समस्याएं थीं? क्या कोई रिफ्लक्स/गैस्ट्रो/ओसोफेगल समस्याएं थीं?
Please comment on any other details about their tonic, clonic, or tonic–clonic seizures (eg significant seizure events/ changes) कृपया उनके टॉनिक, क्लोनिक, या टॉनिक-क्लोनिक दौरे (जैसे महत्वपूर्ण दौरे की घटनाएं/परिवर्तन) के बारे में किसी भी अन्य विवरण पर टिप्पणी करें कृपया उनके टॉनिक, क्लोनिक, या टॉनिक-क्लोनिक दौरे (जैसे महत्वपूर्ण जब्ती घटनाओं/परिवर्तन) के बारे में किसी भी अन्य विवरण पर टिप्पणी करें
What type of seizure was it? यह किस प्रकार का दौरा था? यह किस प्रकार की दौरा था?

A professional medical translation company was hired to complete the Hindi translation, therefore, the community translation column is blank for this language

A group of at least three proofreaders was advantageous

Larger groups reduced the workload for individual proofreaders and enabled more comprehensive review of translations prior to the final proofreading step. For instance, the Spanish proofreading group identified that the word for “boy” and “child” was the same and could thus lead to Spanish speaking families reading sections of the registry as “boy/ adult” rather than “child/ adult.” The author in communication with the translation team (MT) was able to put them in contact with another author (RB) whose first language was Spanish.

Preliminary validation findings are encouraging

Although validation is a separate step beyond translation, the authors compared 107 English and 55 Spanish responses to the Newborn and Infancy module completed since the translations were implemented. This module was selected as being the first module users encounter in the registry, it had the highest completion rate, and responses were thought to be less impacted by the age and genotype of the person with Angelman syndrome. Responses to Likert scale items from the Newborn and Infancy module are shown in Table 3. A series of 25 Chi square tests were conducted, with a Bonferroni adjustment indicating an adjusted alpha level of p = 0.002. Out of the 25 questions, only two demonstrated significant differences between the English and Spanish samples, reflecting that:

  • Spanish speaking parents perceived their infant with Angelman syndrome to be placid more frequently than English speaking parents.

  • English speaking parents perceived their infant with Angelman syndrome to experience more frequent reflux/gastro/oesophageal problems than Spanish speaking parents.

Table 3.

Comparison of English and Spanish language responses to Newborn and Infancy module items

Questions Language 1—Yes all the time 2—Yes, most of the time 3—Yes, some of the time 4—Yes, rarely 5—No, never Unknown Total Chi square tests
Newborn questions n % n % n % n % n % n % N
Were feeding difficulties experienced? English 35 33 29 27 19 18 8 8 15 14 0 0 106 Χ2 (4, 159) = 8.347, p = .08
Spanish 12 23 10 19 8 15 9 17 14 26 0 0 53
Was assistance used at any time in their infancy (eg lactation support, syringes, spooning in pumped milk)? English 18 19 21 22 18 19 9 10 28 30 0 0 94 Χ2 (5, 137) = 4.279, p = .510
Spanish 7 16 7 16 6 14 5 12 17 40 1 2 43
Was there refusal to nurse? English 19 20 9 10 24 26 7 8 29 31 5 5 93 Χ2 (5, 133) = 0.622, p = .987
Spanish 7 18 3 8 10 25 3 8 15 38 2 5 40
Could not latch? English 25 27 21 23 13 14 6 7 22 24 4 4 91 Χ2 (4, 131) = 9.141, p = .104
Spanish 6 15 5 13 8 20 8 20 10 25 3 8 40
Ineffective suck? English 33 36 19 21 16 17 6 7 14 15 4 4 92 Χ2 (5, 132) = 1.113, p = .953
Spanish 13 33 6 15 8 20 3 8 8 20 2 5 40
Was there biting? English 0 0 1 1 18 20 10 11 54 59 9 10 92 Χ2 (5, 132) = 3.885, p = .566
Spanish 1 3 1 3 6 15 5 13 25 63 2 5 40
Were they irritable in association with feeding? English 24 26 17 18 19 21 6 7 24 26 2 2 92 Χ2 (5, 132) = 10.659, p = .059
Spanish 4 10 4 10 10 25 2 5 20 50 0 0 40
Was there vomiting? English 20 19 27 26 15 14 19 18 23 22 1 1 105 Χ2 (5, 156) = 4.471, p = .484
Spanish 7 14 11 22 11 22 6 12 16 31 0 0 51
Was there arching? English 14 13 20 19 29 27 10 9 26 25 7 7 106 Χ2 (5, 157) = 8.824, p = .116
Spanish 4 8 7 14 9 18 3 6 24 47 4 8 51
Did they show excessive movements? English 16 15 15 14 27 25 9 8 32 30 7 7 106 Χ2 (5, 157) = 8.558, p = .128
Spanish 3 6 6 12 9 18 3 6 27 53 3 6 51
Was there difficulties maintaining or regulating proper body temperature? English 4 4 7 7 12 11 7 7 58 55 18 17 106 Χ2 (5, 157) = 14.686, p = .012
Spanish 0 0 2 4 9 18 2 4 38 75 0 0 51
Was there difficulty sleeping? English 43 44 13 13 18 18 8 8 16 16 0 0 98 Χ2 (5, 149) = 6.226, p = .183
Spanish 14 27 6 12 9 18 7 14 15 29 0 0 51
Infancy Questions
Were they happy in the first 12 months of their life? English 31 29 55 51 17 16 3 3 0 0 1 1 107 Χ2 (5, 162) = 3.271, p = .514
Spanish 19 35 31 56 4 7 1 2 0 0 0 0 55
Were they placid in the first 12 months of their life? English 9 9 34 32 22 21 16 15 20 19 4 4 105 Χ2 (5, 160) = 23.817, p = .001
Spanish 18 33 23 42 8 15 3 5 3 5 0 0 55
Were they easy going in the first 12 months of their life? English 22 21 51 48 16 15 14 13 4 4 0 0 107 Χ2 (5, 162) = 10.363, p = .035
Spanish 16 29 19 35 9 16 3 5 8 15 0 0 55
Were they affectionate in the first 12 months of their life? English 22 21 48 45 20 19 6 6 9 8 1 1 106 Χ2 (5, 161) = 9.012, p = .109
Spanish 22 40 16 29 9 16 5 9 3 5 0 0 55
Were there any difficulties with suck/swallow? English 26 24 21 20 29 27 8 7 21 20 2 2 107 Χ2 (5, 161) = 9.641, p = .086
Spanish 9 17 10 19 9 17 4 7 22 41 0 0 54
Were there any difficulties with failure to gain weight? English 18 17 18 17 21 20 2 2 48 45 0 0 107 Χ2 (4, 161) = 7.446, p = .114
Spanish 7 13 9 17 7 13 6 11 25 46 0 0 54
Were there any reflux/gastro/oesophageal problems? English 38 36 26 24 16 15 14 13 11 10 2 2 107 Χ2 (5, 161) = 21.802, p = .001
Spanish 9 17 13 24 11 20 1 2 19 35 1 2 54
Were there any difficulties with transitioning to solid food? English 12 11 15 14 22 21 12 11 43 40 3 3 107 Χ2 (5, 161) = 4.723, p = .451
Spanish 8 15 6 11 7 13 10 19 23 43 0 0 54
Were there any difficulties with asthma/wheezing? English 3 3 2 2 13 12 9 8 79 74 1 1 107 Χ2 (5, 161) = 3.908, p = .563
Spanish 0 0 3 6 5 9 5 9 41 76 0 0 54
Were there any difficulties with coughing? English 1 1 5 5 17 16 17 16 65 61 1 1 106 Χ2 (5, 160) = 0.968, p = .965
Spanish 1 2 2 4 8 15 8 15 35 65 0 0 54
Were there any difficulties with pneumonia? English 1 1 0 0 9 8 11 10 86 80 0 0 107 Χ2 (5, 161) = 4.268, p = .234
Spanish 0 0 0 0 5 9 1 2 48 89 0 0 54
Were there any difficulties with bronchitis? English 1 1 1 1 12 11 9 8 84 79 0 0 107 Χ2 (5, 161) = 3.505, p = .477
Spanish 1 2 0 0 7 13 9 17 37 69 0 0 54
Was there difficulty sleeping? English 38 37 19 19 29 28 8 8 8 8 0 0 102 Χ2 (4, 156) = 6.111, p = .191
Spanish 14 26 8 15 15 28 7 13 10 19 0 0 54

Discussion

The GASR was translated into Spanish, Traditional Chinese, Italian and Hindi. After completion of the community and final proofreading steps, acceptable translations were obtained and made available to the Angelman community. During our experience of managing and governing the translation and proofreading project, we refined the process to reduce burden on the research team and our proofreaders for future translations utilising crowdsourcing [17]. These relate to the process of proofreading, and management of translation projects.

With respect to establishing translation project for future languages, our first step is to source machine translations to create the initial language translation on Crowdin. The second step is to break the registry content into individual tasks based on word count and create a document with (1) links to the Crowdin editor for each task, (2) task name and description, and (3) task word count. The third step is to administer training covering completing tasks in the editing tool, and access to the in-context tool for reviewing content within the website to proofreaders. The translation projects would continue to be managed by the author (MT). Further to this, greater efforts would be made to validate the translations generated. An initial validation of the Newborn and Infancy module of the registry was promising, with few differences between English and Spanish responses.

Potential limitations to the crowdsourcing approach

There were two possible limitations identified in the current study. These limitations relate to the translations, but may also be relevant to validation testing.

Participants were time poor

In some cases, participants were unavailable to complete translation tasks due to competing priorities and responsibilities. Future strategies to assist families may include recruiting a larger number of proofreaders, facilitating support and connection between proofreaders, ensuring that larger proofreading tasks are broken down into smaller chunks, and providing incentives such as a donation to their local Angelman organization.

Community proofreaders were difficult to source for some languages

As participation in the registry was very low for some regions, such as Asia, Africa and the Middle East, it was difficult to source proofreaders for languages spoken in these regions such as Arabic or Hindi. As a result, the team opted for professional translation via vendors who can integrate with Crowdin, with Crowdsourcing reserved for registry revisions once families have become more engaged for the Hindi language.

Conclusion

Crowdsourcing was an effective tool for upgrading translations, facilitating proofreading and integrating translated versions of the Global Angelman Syndrome Registry on an online platform. The availability of translations has led to greater participation and engagement of Angelman populations from regions where Spanish, Italian, Traditional Chinese and Hindi are spoken. The use of Crowdsourcing via online translation software such as Crowdin helps to manage ongoing translation and proofreading needs for research projects and maintain community participation and buy-in. However, further efforts are needed beyond translation to validate the translation of the registry for different communities.

Acknowledgements

We would like to thank the parents and children for the time they took to complete the registry. The authors would like to acknowledge the anonymous proofreaders who generously gave their time and expertise to translate and review the registry content.

Author contributions

MT: developed the concept and design for the study, assisted with the analysis of results, wrote the manuscript, and is the curator of the Global Angelman Syndrome Registry. MB: developed the concept and design for the study, assisted with the analysis of results, and wrote the manuscript. YW, AS: contributed to the design and maintenance of the registry. RB, NZ: contributed to reviewing the translations. MC: assisted in the design of the original cohort, collaborated in the writing and editing of the manuscript. HH: original Principal Investigator, assisted in the design of the original cohort, collaborated in the concept and design of the study and collaborated in the data analysis and editing of the manuscript. JM: manuscript revision and creation of graphs.

Funding

NA.

Availability of data and materials

Data from the Global Angelman Syndrome Registry is available upon request, subject to ethical and legal safeguards. Interested parties can request access to the data by submitting a request form at: https://www.angelmanregistry.info/registry-data-request/. Alternately, a deidentified data set is currently being made available by the Critical Path Institute: https://c-path.org/programs/rdca-dap/overview/platform/. Please email curator@angelmanregistry.info or datarequest@angelmanregistry.info for more information.

Declarations

Ethics approval and consent to participate

Ethical approval for the Global Angelman Syndrome Registry including the translation process was provided by the Mater Misericordiae Ltd Human Research Ethics Committee (Approval Number EC00332).

Consent for publication

NA.

Competing interests

The authors declare that they have no competing interests.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Megan Tones, Email: m.tones@qut.edu.au.

Matthew Bellgard, Email: m.bellgard@uel.co.uk.

References

  • 1.Foundation for Angelman Syndrome Therapeutics [FAST]. What is Angelman Syndrome. Accessed October 4, 2022. https://cureangelman.org.au/what-is-angelman/
  • 2.Rare disease day. Updated 2023. Accessed January 25, 2023. https://www.rarediseaseday.org/
  • 3.European Commission. Updated 2023. Accessed January 25, 2023. https://commission.europa.eu/index_en
  • 4.Agency for Healthcare Research and Quality ([AHRQ], 2020). Registries for Evaluating Patient Outcomes. Published [Date]. Accessed [Date]. URL
  • 5.National Centre for Advancing Translational Sciences [NCATS]. Rare Diseases Registry Program. (RaDaR). Accessed January 25, 2023. https://registries.ncats.nih.gov/
  • 6.Pasquini TLS, Mesfin M, Raskin J. HI Global Registry 2022 Annual Report. Published [Date]. Accessed January 27, 2023. https://congenitalhi.org/wp-content/uploads/2022/12/HI-Global-Registry-2022-Annual-Report.pdf
  • 7.Bohonowych J, Miller J, McCandless SE, Strong TV. The global Prader-Willi syndrome registry: development, launch, and early demographics. Genes (Basel). 2019;10(9):713. doi: 10.3390/genes10090713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Forrest C, Bartek RJ, Rubinstein Y, Groft SC. The case for a global rare-diseases registry. Lancet. 2011;377(9771):1057–1059. doi: 10.1016/S0140-6736(10)60680-0. [DOI] [PubMed] [Google Scholar]
  • 9.Krey I, Heine C, Frömming M, Herrmann J, Møller RS, Weckhuysen S, Courage C, Beblo S, Syrbe S, Lemke JR. The Angelman syndrome online registry—a multilingual approach to support global research. Eur J Med Genet. 2021;64(12):104349. doi: 10.1016/j.ejmg.2021.104349. [DOI] [PubMed] [Google Scholar]
  • 10.Epstein J, Santo RM, Guillemin F. A review of guidelines for cross-cultural adaptation of questionnaires could not bring out a consensus. J Clin Epidemiol. 2015;68(4):435–441. doi: 10.1016/j.jclinepi.2014.11.021. [DOI] [PubMed] [Google Scholar]
  • 11.Anastasiou D, Gupta R. Comparison of crowdsourcing translation with machine translation. J Inf Sci. 2011;37(6):63–69. doi: 10.1177/0165551511418760. [DOI] [Google Scholar]
  • 12.Qun L, Xiaojun Z. Machine translation. In: Chan S, editor. The Routledge encyclopedia of translation technology. Abingdon: Routledge; 2015. pp. 105–119. [Google Scholar]
  • 13.O’Hagan M. Computer-aided translation (CAT) In: Baker M, Saldanha C, editors. Routledge encyclopedia of translation studies. Abingdon: Routledge; 2009. pp. 48–51. [Google Scholar]
  • 14.Wazny K. Crowdsourcing” ten years in: a review. J Glob Health. 2017;7(2):020602. doi: 10.7189/jogh.07.020602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Bassi H, Lee CJ, Misener L, Johnson AM. Exploring the characteristics of crowdsourcing: an online observational study. J Inf Sci. 2020;46(3):291–312. doi: 10.1177/0165551519828626. [DOI] [Google Scholar]
  • 16.Behmen D, Marušić A, Puljak L. Capacity building for knowledge translation: a survey about the characteristics and motivation of volunteer translators of Cochrane plain language summaries. J Evid Based Med. 2019;12(2):147–154. doi: 10.1111/jebm.12345. [DOI] [PubMed] [Google Scholar]
  • 17.Blohm I, Zogaj S, Bretschneider U, Leimeister JM. How to manage crowdsourcing platforms effectively. Calif Manag Rev. 2018;60(2):122–149. doi: 10.1177/000812561773825. [DOI] [Google Scholar]
  • 18.Tones M, Cross M, Simons C, Napier KR, Hunter A, Bellgard MI, Heussler H. Research protocol: the initiation, design and establishment of the Global Angelman Syndrome Registry. J Intellect Disabil Res. 2018;62(5):431–443. doi: 10.1111/jir.12482. [DOI] [PubMed] [Google Scholar]
  • 19.Hammond E, Youngs L, Bellgard M, Dawkins HSP. 33 Australasian neuromuscular disease registry (conference abstract) Neuromuscul Disorders. 2012;22(9–10):881. doi: 10.1016/j.nmd.2012.06.258. [DOI] [Google Scholar]
  • 20.Bellgard M, Macgregor A, Janon F, et al. A modular approach to disease registry design: successful adoption of an internet-based rare disease registry. Hum Mutat. 2012;33(10):E2356–E2366. doi: 10.1002/humu.22154. [DOI] [PubMed] [Google Scholar]
  • 21.Bellgard M, Beroud C, Parkinson K, et al. Dispelling myths about rare disease registry system development. Source Code for Biol Med. 2013;9(1):1–7. doi: 10.1186/1751-0473-9-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Bellgard M, Render L, Radochonski M, Hunter A. Second generation registry framework. Source Code for Biol Med. 2014;9(14):1–6. doi: 10.1186/1751-0473-9-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Bladen C, Salgado D, Monges S, et al. The TREAT-NMD DMD Global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015;36(4):395–402. doi: 10.1002/humu.22758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Bellgard M, Walker C, Napier K, et al. Design of the familial hypercholesterolaemia Australasia network registry: creating opportunities for greater international collaboration. J Atheroscler Thromb. 2017;24(10):1075–1084. doi: 10.5551/jat.37507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Napier K, Pang J, Lamont L, et al. A web-based registry for familial hypercholesterolaemia. Heart Lung Circ. 2017;26(6):635–639. doi: 10.1016/j.hlc.2016.10.019. [DOI] [PubMed] [Google Scholar]
  • 26.Koeks Z, Bladen C, Salgado D, et al. Clinical outcomes in duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD Global Database. J Neuromuscul Dis. 2017;4(4):293–306. doi: 10.3233/JND-170280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Napier K, Tones M, Simons C, et al. A web-based, patient driven registry for Angelman syndrome: the global Angelman syndrome registry. Orphanet J Rare Dis. 2017;12(134):1–5. doi: 10.1186/s13023-017-0686-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Bellgard M, Napier K, Bittles A, et al. Design of a framework for the deployment of collaborative independent rare disease-centric registries: gaucher disease registry model. Blood Cells Mol Dis. 2018;68:232–238. doi: 10.1016/j.bcmd.2017.01.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ng D, Hooper A, Bellgard M, Burnett J. The role of patient registries for rare genetic lipid disorders. Curr Opin Lipidol. 2018;29(2):156–162. doi: 10.1097/MOL.0000000000000485. [DOI] [PubMed] [Google Scholar]
  • 30.Schultz A, Marsh JA, Saville BR, et al. Trial refresh: a case for an adaptive platform trial for pulmonary exacerbations of cystic fibrosis. Front Pharmacol. 2019;28(10):301. doi: 10.3389/fphar.2019.00301.PMID:30983998;PMCID:PMC6447696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Napier KR, Hooper AJ, Ng DM, et al. Design, development and deployment of a web-based patient registry for rare genetic lipid disorders. Pathology. 2020;52(4):447–452. doi: 10.1016/j.pathol.2020.02.002. [DOI] [PubMed] [Google Scholar]
  • 32.Ramsay J, Marsh J, Pedrana A, et al. A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C. BMC Infect Dis. 2020;20:802. doi: 10.1186/s12879-020-05531-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Graham C, Molster C, Baynam G, et al. Current trends in biobanking for rare diseases: a review. J Biorepos Sci Appl Med. 2014;2:49–61. doi: 10.2147/BSAM.S46707. [DOI] [Google Scholar]
  • 34.Vucic S, Wray N, Henders A, et al. MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(5–6):321–328. doi: 10.1080/21678421.2021.1980889. [DOI] [PubMed] [Google Scholar]
  • 35.Bellgard MI, Snelling T, McGree JM. RD-RAP: beyond rare disease patient registries, devising a comprehensive data and analytic framework. Orphanet J Rare Dis. 2019 doi: 10.1186/s13023-019-1139-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Leader G, Whelan S, Chonaill NN, et al. Association between early and current gastro-intestinal symptoms and co-morbidities in children and adolescents with Angelman syndrome. J Intellect Disabil Res. 2022;66(11):865–879. doi: 10.1111/jir.12975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Leader G, Gilligan R, Whelan S, et al. Relationships between challenging behavior and gastrointestinal symptoms, sleep problems, and internalizing and externalizing symptoms in children and adolescents with Angelman syndrome. Res Dev Disabil. 2022;128(104293):1–13. doi: 10.1016/j.ridd.2022.104293. [DOI] [PubMed] [Google Scholar]
  • 38.Roche L, Tones M, Cross M, et al. An overview of the adaptive behaviour profile in young children with Angelman Syndrome: insights from the global Angelman Syndrome Registry. Adv Neurodev Disord. 2022;6:442–455. doi: 10.1007/s41252-022-00278-2. [DOI] [Google Scholar]
  • 39.Roche L, Tones M, Williams MG, et al. Caregivers report on the pathway to a formal diagnosis of angelman syndrome: a comparison across genetic etiologies within the Global Angelman Syndrome Registry. Adv Neurodev Disord. 2021;5:193–203. doi: 10.1007/s41252-021-00195-w. [DOI] [Google Scholar]
  • 40.Crowdin Enterprise (n.d.). https://crowdin.com/enterprise. Accessed 20 February 2023

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data from the Global Angelman Syndrome Registry is available upon request, subject to ethical and legal safeguards. Interested parties can request access to the data by submitting a request form at: https://www.angelmanregistry.info/registry-data-request/. Alternately, a deidentified data set is currently being made available by the Critical Path Institute: https://c-path.org/programs/rdca-dap/overview/platform/. Please email curator@angelmanregistry.info or datarequest@angelmanregistry.info for more information.


Articles from Orphanet Journal of Rare Diseases are provided here courtesy of BMC

RESOURCES